mProve Health, a provider of mobile technologies used by life science organizations to connect and engage patients with global clinical research studies, announced unprecedented 12-month growth and the addition of 25% more new pharmaceutical companies and CROs to its client base.
With contracts for research studies at 18 of the top 20 pharmaceutical companies and more than 15,000 clinical research sites in over 60 countries engaged to enroll patients on mProve’s applications, the company is expanding. mProve Health recently made a strategic move into new, industrial- and tech-inspired, open-concept offices in the Washington, D.C., metro area. This comes following 16 new hires in the past 12 months and the establishment of a U.K.-based team in London.
“mProve Health has experienced record growth in the past 12 months,” said Jeff Lee, founder and CEO. “Our traction among top 20 pharmaceutical companies is a direct result of our team and their ability to consistently deliver high-quality software and services. Opening our new Washington, D.C., headquarters, outfitted to attract and retain the best and brightest, was a strategic move to best position us for the future.” Leaving behind a startup-style office space, and moving the company into new, custom-designed headquarters will allow mProve Health to plant firm roots.
mProve Health, founded in 2010, launched with a mobile technology product for patient recruitment that provides a call-to-action (i.e. “text Keyword to Number”) to existing clinical research study advertisements. It has since expanded its offerings to include mobile technology for patient engagement and electronic patient reported outcomes (ePRO). Its ePRO product, mPulse, has contributed the most to revenue growth in the past 12 months, due to a 200 percent increase in new study contracts. mPulse is uniquely positioned in the marketplace because it delivers validated trial instruments, or market research surveys, along with patient engagement features, such as reminders, visit schedule details, and reference information, all in a single mobile app. This creates “one stop shop” access to study services that improve the patient’s experience, and boost utilization of diaries, patient compliance and study completion rates.
Commenting on the rapid development of the market, Jim Kremidas, executive director of the Association of Clinical Research Professionals (ACRP), said: “Fueled by the pharmaceutical industry’s move to make clinical trials more patient-centric and operationally efficient, the demand for patient engagement technologies is growing. This growth is a testament to the industry’s focus on delivering a new breed of solutions with a mission to improve the lives of patients and the clinical research sites supporting them.”
mProve Health is Lee’s fourth mobile technology venture. Co-founded with Denis Curtin, Ph.D., CSO, a pharmacologist and pharmaceutical industry veteran, the company is challenging the legacy of patient technology used in clinical research studies. By expanding mProve’s foothold in Washington, D.C., the leadership team continues to remain actively involved with regulators shaping the future of mHealth policy.
